Bio-Path Holdings
  • About Bio-Path
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us

SEC Form 8-K: Press Release dated May 1, 2025

BPTH_8-K_20250502

SEC Form 8-K: Entry into a Material Definitive Agreement

BPTH_8-K_20250429

SEC Form 1-A

BPTH_Form_1-A_20250411

SEC: Withdrawal of Registration Statement on Form S-1

BPTH_25-3664-12__RW_20250409

SEC Form 8-K: Entry into a Material Definitive Agreement

BPTH_8-K_25-10724

SEC Form 8-K: Press Release dated March 28, 2025

BPTH20250327_8-K

SEC Form 10-K: For the fiscal year ended December 31, 2024

BPTH_Form_10-K_20250327

SEC Form 8-K: Press Release dated March 18, 2025

BPTH_20250318_8-K

SEC Form 8-K: Entry into a Material Definitive Agreement

BPTH_8-K_20250307

SEC Form 8-K

BPTH_20250217_8-K

Bio-Path Holdings

All Rights Reserved

Office:

4710 Bellaire Blvd, Suite 210
Bellaire, TX 77401

T: (832) 742-1357

R&D:

5455 Dashwood Street, Suite 300
Bellaire, TX 77401

T: (832) 742-1357

logo
  • About Bio-Path
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us